Elevated IL-6 levels are associated with inferior clinical outcome. (A) Using a cut point of 12 pg/mL for the entire cohort (n = 45), 5-year EFS was 20.6% ± 10% for those with high IL-6 levels at diagnosis vs 43.4% ± 12% for those with low IL-6 levels (log-rank P = .036). (B) For LR patients (n = 27), a cut point of 12 pg/mL identified patients with inferior EFS (17.3% ± 11% vs 82.5% ± 11% for high vs low IL-6 levels, P = .0003). (C) Inferior OS was also noted for the LR patients (cut point of 12 pg/mL, 39% ± 14.8% vs 90.1% ± 8.7% for high vs low IL-6 levels, P = .007, n = 27). No other cytokines were associated with clinical outcome in our cohort. Notably, levels of IL-8 (D) and IL-10 (E) were not associated with EFS. Estimates of EFS are reported with corresponding Greenwood standard errors. Groups were compared for significant differences by the log-rank test.